Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$10.19−1.16 (-10.22%)

Close on Nov 12, 2026Market cap $655.77MP/E –Yield –

Cullinan Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Cullinan Therapeutics's EV/EBITDA was 0.2× on Jul 31, 2023.

Period	Period end	Value	Change (pts)
2023	Jul 31, 2023	0.2×	+0.2
2022	Aug 31, 2022	0.0×	–

See a number that looks wrong?